Plans to produce Pfizer’s Covid-19 vaccine in Cape Town may be scaled back because of waning demand for the shots, according to the head of the company’s South African manufacturing partner. About 100 million doses a year are slated to be packaged and filled at a plant controlled by the BioVac Institute, partly owned by the South African government, which would become the first Southern Hemisphere facility to use the messenger RNA technology underlying the Pfizer-BioNTech version.
from Engineering News | Home https://ift.tt/NZ9vIET
